LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 89

Search options

  1. Article ; Online: Imaging PD-L1 Expression in Melanoma Brain Metastases.

    Nimmagadda, Sridhar

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    2021  Volume 63, Issue 6, Page(s) 897–898

    MeSH term(s) B7-H1 Antigen/metabolism ; Brain Neoplasms/diagnostic imaging ; Fluorodeoxyglucose F18 ; Humans ; Melanoma/diagnostic imaging ; Melanoma/pathology ; Positron-Emission Tomography/methods ; Radiopharmaceuticals
    Chemical Substances B7-H1 Antigen ; Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2021-11-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80272-4
    ISSN 1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
    ISSN (online) 1535-5667
    ISSN 0097-9058 ; 0161-5505 ; 0022-3123
    DOI 10.2967/jnumed.121.263209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 328: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.

    Nimmagadda, Sridhar

    Cancers

    2020  Volume 12, Issue 11

    Abstract: Therapeutics targeting programmed death ligand 1 (PD-L1) protein and its receptor PD-1 are now dominant players in restoring anti-tumor immune responses. PD-L1 detection by immunohistochemistry (IHC) is emerging as a reproducible biomarker for guiding ... ...

    Abstract Therapeutics targeting programmed death ligand 1 (PD-L1) protein and its receptor PD-1 are now dominant players in restoring anti-tumor immune responses. PD-L1 detection by immunohistochemistry (IHC) is emerging as a reproducible biomarker for guiding patient stratification for those therapies in some cancers. However, PD-L1 expression in the tumor microenvironment is highly complex. It is upregulated by aberrant genetic alterations, and is highly regulated at the transcriptional, posttranscriptional, and protein levels. Thus, PD-L1 IHC is inadequate to fully understand the relevance of PD-L1 levels in the whole body and their dynamics to improve therapeutic outcomes. Imaging technologies could potentially assist in meeting that need. Early clinical investigations show promising results in quantifying PD-L1 expression in the whole body by positron emission tomography (PET). Within this context, this review summarizes advancements in regulation of PD-L1 expression and imaging agents, and in PD-L1 PET for drug development, and discusses opportunities and challenges presented by these innovations for guiding immune checkpoint therapy (ICT).
    Language English
    Publishing date 2020-10-29
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers12113173
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: An optimized radiosynthesis of [

    Holt, Daniel P / Kumar, Dhiraj / Nimmagadda, Sridhar / Dannals, Robert F

    Journal of labelled compounds & radiopharmaceuticals

    2023  Volume 66, Issue 2, Page(s) 47–54

    Abstract: A radiochemical synthesis of [ ...

    Abstract A radiochemical synthesis of [
    MeSH term(s) Humans ; B7-H1 Antigen ; Positron-Emission Tomography/methods ; Fluorine Radioisotopes ; Radiopharmaceuticals ; Radiochemistry/methods
    Chemical Substances CD274 protein, human ; B7-H1 Antigen ; Fluorine Radioisotopes ; Radiopharmaceuticals
    Language English
    Publishing date 2023-01-17
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 196095-7
    ISSN 1099-1344 ; 0362-4803 ; 0022-2135
    ISSN (online) 1099-1344
    ISSN 0362-4803 ; 0022-2135
    DOI 10.1002/jlcr.4012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1332: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Ovarian Cancer Targeted Theranostics.

    Nimmagadda, Sridhar / Penet, Marie-France

    Frontiers in oncology

    2020  Volume 9, Page(s) 1537

    Abstract: Ovarian cancer is a leading cause of death from gynecological malignancies. Although the prognosis is quite favorable if detected at an early stage, the vast majority of cases are diagnosed at an advanced stage, when 5-year survival rates are only 30-40%. ...

    Abstract Ovarian cancer is a leading cause of death from gynecological malignancies. Although the prognosis is quite favorable if detected at an early stage, the vast majority of cases are diagnosed at an advanced stage, when 5-year survival rates are only 30-40%. Most recurrent ovarian tumors are resistant to traditional therapies underscoring the need for new therapeutic options. Theranostic agents, that combine diagnostic and therapeutic capabilities, are being explored to better detect, diagnose and treat ovarian cancer. To minimize morbidity, improve survival rates, and eventually cure patients, new strategies are needed for early detection and for delivering specifically anticancer therapies to tumor sites. In this review we will discuss various molecular imaging modalities and targets that can be used for imaging, therapeutic and theranostic agent development for improved diagnosis and treatment of ovarian cancer.
    Language English
    Publishing date 2020-01-21
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2019.01537
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with

    Leland, Pamela / Kumar, Dhiraj / Nimmagadda, Sridhar / Bauer, Steven R / Puri, Raj K / Joshi, Bharat H

    Journal of translational medicine

    2023  Volume 21, Issue 1, Page(s) 636

    Language English
    Publishing date 2023-09-19
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2118570-0
    ISSN 1479-5876 ; 1479-5876
    ISSN (online) 1479-5876
    ISSN 1479-5876
    DOI 10.1186/s12967-023-04496-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with

    Leland, Pamela / Kumar, Dhiraj / Nimmagadda, Sridhar / Bauer, Steven R / Puri, Raj K / Joshi, Bharat H

    Journal of translational medicine

    2023  Volume 21, Issue 1, Page(s) 367

    Abstract: Background: Chimeric antigen receptor (CAR) T cell therapy is an exciting cell-based cancer immunotherapy. Unfortunately, CAR-T cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and neurotoxicity. The mechanism ... ...

    Abstract Background: Chimeric antigen receptor (CAR) T cell therapy is an exciting cell-based cancer immunotherapy. Unfortunately, CAR-T cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and neurotoxicity. The mechanism of these serious adverse events (SAEs) and how homing, distribution and retention of CAR-T cells contribute to toxicities is not fully understood. Enabling in vitro methods to allow meaningful, sensitive in vivo biodistribution studies is needed to better understand CAR-T cell disposition and its relationship to both effectiveness and safety of these products.
    Methods: To determine if radiolabelling of CAR-T cells could support positron emission tomography (PET)-based biodistribution studies, we labeled IL-13Rα2 targeting scFv-IL-13Rα2-CAR-T cells (CAR-T cells) with
    Results: We observed that radiolabeling of CAR-T cells with
    Conclusions: Importantly, radiolabeling has minimal impact on biological product attributes including potency of CAR-T cells towards IL-13Rα2 positive tumor cells but not IL-13Rα2 negative cells as measured by cytolytic activity and release of IFN-γ. Thus, IL-13Rα2 targeting CAR-T cells radiolabeled with
    MeSH term(s) Zirconium/pharmacokinetics ; Radioisotopes/pharmacokinetics ; Positron-Emission Tomography ; Cell Tracking/methods ; Immunotherapy, Adoptive ; Single-Chain Antibodies ; T-Lymphocytes/cytology ; Tissue Distribution ; Jurkat Cells ; Animals ; Mice ; Cell Proliferation ; Cell Survival
    Chemical Substances Zirconium (C6V6S92N3C) ; Radioisotopes ; Single-Chain Antibodies
    Language English
    Publishing date 2023-06-07
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 2118570-0
    ISSN 1479-5876 ; 1479-5876
    ISSN (online) 1479-5876
    ISSN 1479-5876
    DOI 10.1186/s12967-023-04142-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging.

    Nimmagadda, Sridhar

    Frontiers in oncology

    2012  Volume 2, Page(s) 46

    Abstract: Chemokine/chemokine receptor interactions play diverse roles in cell migration and homeostasis. Emerging evidence suggests that cancer cells co-opt chemokine networks for survival, proliferation, immune evasion, and metastasis. Most of the chemokine ... ...

    Abstract Chemokine/chemokine receptor interactions play diverse roles in cell migration and homeostasis. Emerging evidence suggests that cancer cells co-opt chemokine networks for survival, proliferation, immune evasion, and metastasis. Most of the chemokine receptors are reported to be involved in tumor progression. Given their extensive implication in cancer progression, several chemokine receptor/ligand axes are considered as potential therapeutic targets. This review provides a survey of chemokine receptor expression in cancer and evaluates the potential of chemokine receptor imaging as a tool for molecular characterization of cancer.
    Language English
    Publishing date 2012-05-30
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X ; 2234-943X
    ISSN (online) 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2012.00046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.

    Oldan, Jorge D / Schroeder, Jennifer A / Hoffman-Censits, Jean / Rathmell, W Kimryn / Milowsky, Matthew I / Solnes, Lilja B / Nimmagadda, Sridhar / Gorin, Michael A / Khandani, Amir H / Rowe, Steven P

    PET clinics

    2024  Volume 19, Issue 2, Page(s) 197–206

    Abstract: Renal cell carcinoma (RCC) and urothelial carcinoma (UC) are two of the most common genitourinary malignancies. 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG) can play an important role in the evaluation of patients with RCC and UC. In addition to the ... ...

    Abstract Renal cell carcinoma (RCC) and urothelial carcinoma (UC) are two of the most common genitourinary malignancies. 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG) can play an important role in the evaluation of patients with RCC and UC. In addition to the clinical utility of 18F-FDG PET to evaluate for metastatic RCC or UC, the shift in molecular imaging to focus on specific ligand-receptor interactions should provide novel diagnostic and therapeutic opportunities in genitourinary malignancies. In combination with the rise of artificial intelligence, our ability to derive imaging biomarkers that are associated with treatment selection, response assessment, and overall patient prognostication will only improve.
    MeSH term(s) Humans ; Carcinoma, Renal Cell/diagnostic imaging ; Carcinoma, Renal Cell/secondary ; Fluorodeoxyglucose F18 ; Carcinoma, Transitional Cell/diagnostic imaging ; Artificial Intelligence ; Urinary Bladder Neoplasms/therapy ; Kidney ; Urologic Neoplasms/diagnostic imaging ; Tomography, X-Ray Computed ; Positron-Emission Tomography/methods ; Kidney Neoplasms/diagnostic imaging ; Positron Emission Tomography Computed Tomography
    Chemical Substances Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2024-01-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2764575-7
    ISSN 1879-9809 ; 1556-8598
    ISSN (online) 1879-9809
    ISSN 1556-8598
    DOI 10.1016/j.cpet.2023.12.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Einzelsignatur: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET.

    Sharma, Ajay Kumar / Gupta, Kuldeep / Mishra, Akhilesh / Lofland, Gabriela / Marsh, Ian / Kumar, Dhiraj / Ghiaur, Gabriel / Imus, Philip / Rowe, Steven P / Hobbs, Robert F / Gocke, Christian B / Nimmagadda, Sridhar

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

    2024  Volume 11, Issue 16, Page(s) e2308617

    Abstract: The limited availability of molecularly targeted low-molecular-weight imaging agents for monitoring multiple myeloma (MM)-targeted therapies has been a significant challenge in the field. In response, a first-in-class peptide-based radiotracer, [ ...

    Abstract The limited availability of molecularly targeted low-molecular-weight imaging agents for monitoring multiple myeloma (MM)-targeted therapies has been a significant challenge in the field. In response, a first-in-class peptide-based radiotracer, [
    MeSH term(s) Gallium Radioisotopes ; Multiple Myeloma/drug therapy ; Multiple Myeloma/metabolism ; Multiple Myeloma/diagnostic imaging ; Animals ; ADP-ribosyl Cyclase 1/metabolism ; Mice ; Humans ; Positron-Emission Tomography/methods ; Radiopharmaceuticals/pharmacokinetics ; Disease Models, Animal ; Peptides/metabolism ; Membrane Glycoproteins/metabolism ; Cell Line, Tumor
    Chemical Substances Gallium Radioisotopes ; ADP-ribosyl Cyclase 1 (EC 3.2.2.6) ; Gallium-68 (98B30EPP5S) ; Radiopharmaceuticals ; Peptides ; CD38 protein, human (EC 3.2.2.5) ; Membrane Glycoproteins
    Language English
    Publishing date 2024-02-29
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2808093-2
    ISSN 2198-3844 ; 2198-3844
    ISSN (online) 2198-3844
    ISSN 2198-3844
    DOI 10.1002/advs.202308617
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1.

    Ludwig, Seth D / Meksiriporn, Bunyarit / Tan, Jiacheng / Kureshi, Rakeeb / Mishra, Akhilesh / Kaeo, Kyle J / Zhu, Angela / Stavrakis, Georgia / Lee, Stephen J / Schodt, David J / Wester, Michael J / Kumar, Dhiraj / Lidke, Keith A / Cox, Andrea L / Dooley, Helen M / Nimmagadda, Sridhar / Spangler, Jamie B

    Cell chemical biology

    2024  

    Abstract: Programmed death-ligand 1 (PD-L1) drives inhibition of antigen-specific T cell responses through engagement of its receptor programmed death-1 (PD-1) on activated T cells. Overexpression of these immune checkpoint proteins in the tumor microenvironment ... ...

    Abstract Programmed death-ligand 1 (PD-L1) drives inhibition of antigen-specific T cell responses through engagement of its receptor programmed death-1 (PD-1) on activated T cells. Overexpression of these immune checkpoint proteins in the tumor microenvironment has motivated the design of targeted antibodies that disrupt this interaction. Despite clinical success of these antibodies, response rates remain low, necessitating novel approaches to enhance performance. Here, we report the development of antibody fusion proteins that block immune checkpoint pathways through a distinct mechanism targeting molecular trafficking. By engaging multiple receptor epitopes on PD-L1, our engineered multiparatopic antibodies induce rapid clustering, internalization, and degradation in an epitope- and topology-dependent manner. The complementary mechanisms of ligand blockade and receptor downregulation led to more durable immune cell activation and dramatically reduced PD-L1 availability in mouse tumors. Collectively, these multiparatopic antibodies offer mechanistic insight into immune checkpoint protein trafficking and how it may be manipulated to reprogram immune outcomes.
    Language English
    Publishing date 2024-03-27
    Publishing country United States
    Document type Journal Article
    ISSN 2451-9448
    ISSN (online) 2451-9448
    DOI 10.1016/j.chembiol.2024.02.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top